A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)

J2T-MC-KGAK -

The reason for this study is to assess the impact of lebrikizumab on vaccine immune response in adult participants with moderate to severe atopic dermatitis (AD).

Trial Summary

Age Range
18 - 55 years
Conditions the trial is for
Atopic Dermatitis (Eczema)
What the trial is testing?
lebrikizumab
Could I receive a Placebo?
Yes
Enrollment Goal
254
Trial Dates
Nov 17, 2020 - Sep 30, 2022
How long will I be in the trial?
The study will last up to 32 weeks and may include up to 11 visits.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must have chronic atopic dermatitis

  • Participants must have had unsatisfactory results with existing medications applied to the skin

Participants Must Not:

  • Participants must not have a history of anaphalaxis (severe, life threatening allergic reaction)

  • Participants must not have certain types of infection

  • Participants must not have other skin conditions or diseases that would interfere with the study

  • Participants must not have a history of certain types of cancers

  • Participants must not be pregnant or breastfeeding

  • Participants must have not received any tetanus-containing vaccine within approximately 5 years of baseline

  • Participants must have never received a meningitis vaccine (MCV), or have received only 1 prior MCV at least 4 years prior to baseline

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources